Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Depression: HELP
Articles from Harvard University
Based on 2,351 articles published since 2008
||||

These are the 2351 published articles about Depression that originated from Harvard University during 2008-2019.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
1 Guideline Interventions to Prevent Perinatal Depression: US Preventive Services Task Force Recommendation Statement. 2019

Anonymous3491079 / Curry, Susan J / Krist, Alex H / Owens, Douglas K / Barry, Michael J / Caughey, Aaron B / Davidson, Karina W / Doubeni, Chyke A / Epling, John W / Grossman, David C / Kemper, Alex R / Kubik, Martha / Landefeld, C Seth / Mangione, Carol M / Silverstein, Michael / Simon, Melissa A / Tseng, Chien-Wen / Wong, John B. ·University of Iowa, Iowa City. · Fairfax Family Practice Residency, Fairfax, Virginia. · Virginia Commonwealth University, Richmond. · Veterans Affairs Palo Alto Health Care System, Palo Alto, California. · Stanford University, Stanford, California. · Harvard Medical School, Boston, Massachusetts. · Oregon Health & Science University, Portland. · Feinstein Institute for Medical Research at Northwell Health, Manhasset, New York. · University of Pennsylvania, Philadelphia. · Virginia Tech Carilion School of Medicine, Roanoke. · Kaiser Permanente Washington Health Research Institute, Seattle. · Nationwide Children's Hospital, Columbus, Ohio. · Temple University, Philadelphia, Pennsylvania. · University of Alabama at Birmingham. · University of California, Los Angeles. · Boston University, Boston, Massachusetts. · Northwestern University, Evanston, Illinois. · University of Hawaii, Honolulu. · Pacific Health Research and Education Institute, Honolulu, Hawaii. · Tufts University, Medford, Massachusetts. ·JAMA · Pubmed #30747971.

ABSTRACT: Importance: Perinatal depression, which is the occurrence of a depressive disorder during pregnancy or following childbirth, affects as many as 1 in 7 women and is one of the most common complications of pregnancy and the postpartum period. It is well established that perinatal depression can result in adverse short- and long-term effects on both the woman and child. Objective: To issue a new US Preventive Services Task Force (USPSTF) recommendation on interventions to prevent perinatal depression. Evidence Review: The USPSTF reviewed the evidence on the benefits and harms of preventive interventions for perinatal depression in pregnant or postpartum women or their children. The USPSTF reviewed contextual information on the accuracy of tools used to identify women at increased risk of perinatal depression and the most effective timing for preventive interventions. Interventions reviewed included counseling, health system interventions, physical activity, education, supportive interventions, and other behavioral interventions, such as infant sleep training and expressive writing. Pharmacological approaches included the use of nortriptyline, sertraline, and omega-3 fatty acids. Findings: The USPSTF found convincing evidence that counseling interventions, such as cognitive behavioral therapy and interpersonal therapy, are effective in preventing perinatal depression. Women with a history of depression, current depressive symptoms, or certain socioeconomic risk factors (eg, low income or young or single parenthood) would benefit from counseling interventions and could be considered at increased risk. The USPSTF found adequate evidence to bound the potential harms of counseling interventions as no greater than small, based on the nature of the intervention and the low likelihood of serious harms. The USPSTF found inadequate evidence to assess the benefits and harms of other noncounseling interventions. The USPSTF concludes with moderate certainty that providing or referring pregnant or postpartum women at increased risk to counseling interventions has a moderate net benefit in preventing perinatal depression. Conclusions and Recommendation: The USPSTF recommends that clinicians provide or refer pregnant and postpartum persons who are at increased risk of perinatal depression to counseling interventions. (B recommendation).

2 Guideline Screening for Depression in Adults: US Preventive Services Task Force Recommendation Statement. 2016

Siu, Albert L / Anonymous2730856 / Bibbins-Domingo, Kirsten / Grossman, David C / Baumann, Linda Ciofu / Davidson, Karina W / Ebell, Mark / García, Francisco A R / Gillman, Matthew / Herzstein, Jessica / Kemper, Alex R / Krist, Alex H / Kurth, Ann E / Owens, Douglas K / Phillips, William R / Phipps, Maureen G / Pignone, Michael P. ·Mount Sinai School of Medicine, New York2James J. Peters Veterans Affairs Medical Center, Bronx, New York. · University of California, San Francisco. · Group Health Research Institute, Seattle, Washington. · University of Wisconsin, Madison. · Columbia University, New York, New York. · University of Georgia, Athens. · Pima County Department of Health, Tucson, Arizona. · Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts. · Independent consultant, Washington, DC. · Duke University, Durham, North Carolina. · Fairfax Family Practice, Fairfax, Virginia13Virginia Commonwealth University, Richmond. · New York University, New York. · Veterans Affairs Palo Alto Health Care System, Palo Alto, California16Stanford University, Stanford, California. · University of Washington, Seattle. · Brown University, Providence, Rhode Island. · University of North Carolina, Chapel Hill. ·JAMA · Pubmed #26813211.

ABSTRACT: DESCRIPTION: Update of the 2009 US Preventive Services Task Force (USPSTF) recommendation on screening for depression in adults. METHODS: The USPSTF reviewed the evidence on the benefits and harms of screening for depression in adult populations, including older adults and pregnant and postpartum women; the accuracy of depression screening instruments; and the benefits and harms of depression treatment in these populations. POPULATION: This recommendation applies to adults 18 years and older. RECOMMENDATION: The USPSTF recommends screening for depression in the general adult population, including pregnant and postpartum women. Screening should be implemented with adequate systems in place to ensure accurate diagnosis, effective treatment, and appropriate follow-up. (B recommendation).

3 Guideline Screening, assessment, and care of anxiety and depressive symptoms in adults with cancer: an American Society of Clinical Oncology guideline adaptation. 2014

Andersen, Barbara L / DeRubeis, Robert J / Berman, Barry S / Gruman, Jessie / Champion, Victoria L / Massie, Mary Jane / Holland, Jimmie C / Partridge, Ann H / Bak, Kate / Somerfield, Mark R / Rowland, Julia H / Anonymous2830791. ·Barbara L. Andersen, The Ohio State University, Columbus, OH · Robert J. DeRubeis, University of Pennsylvania, Philadelphia, PA · Barry S. Berman, Broward Health Medical Center, Fort Lauderdale, FL · Jessie Gruman, Center for Advancing Health, Washington, DC · Victoria L. Champion, Indiana University, Indianapolis, IN · Mary Jane Massie, Jimmie C. Holland, Memorial Sloan-Kettering Cancer Institute, New York, NY · Ann H. Partridge, Dana Farber Cancer Institute, Boston, MA · Kate Bak and Mark R. Somerfield, American Society of Clinical Oncology, Alexandria, VA · Julia H. Rowland, National Cancer Institute, Bethesda, MD. ·J Clin Oncol · Pubmed #24733793.

ABSTRACT: PURPOSE: A Pan-Canadian Practice Guideline on Screening, Assessment, and Care of Psychosocial Distress (Depression, Anxiety) in Adults With Cancer was identified for adaptation. METHODS: American Society of Clinical Oncology (ASCO) has a policy and set of procedures for adapting clinical practice guidelines developed by other organizations. The guideline was reviewed for developmental rigor and content applicability. RESULTS: On the basis of content review of the pan-Canadian guideline, the ASCO panel agreed that, in general, the recommendations were clear, thorough, based on the most relevant scientific evidence, and presented options that will be acceptable to patients. However, for some topics addressed in the pan-Canadian guideline, the ASCO panel formulated a set of adapted recommendations based on local context and practice beliefs of the ad hoc panel members. It is recommended that all patients with cancer be evaluated for symptoms of depression and anxiety at periodic times across the trajectory of care. Assessment should be performed using validated, published measures and procedures. Depending on levels of symptoms and supplementary information, differing treatment pathways are recommended. Failure to identify and treat anxiety and depression increases the risk for poor quality of life and potential disease-related morbidity and mortality. This guideline adaptation is part of a larger survivorship guideline series. CONCLUSION: Although clinicians may not be able to prevent some of the chronic or late medical effects of cancer, they have a vital role in mitigating the negative emotional and behavioral sequelae. Recognizing and treating effectively those who manifest symptoms of anxiety or depression will reduce the human cost of cancer.

4 Editorial Perinatal Depression: Recommendations for Prevention and the Challenges of Implementation. 2019

Freeman, Marlene P. ·Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts. ·JAMA · Pubmed #30747953.

ABSTRACT: -- No abstract --

5 Editorial From depression to anxiety, and back. 2017

Bui, Eric / Fava, Maurizio. ·Massachusetts General Hospital, Boston, MA, USA. · Harvard Medical School, Boston, MA, USA. ·Acta Psychiatr Scand · Pubmed #28865404.

ABSTRACT: -- No abstract --

6 Editorial Lessons Learned From the VA Augmentation and Switching Treatments for Improving Depression Outcomes (VAST-D) Study. 2017

Fava, Maurizio. ·Division of Clinical Research, Massachusetts General Hospital, Boston. ·JAMA · Pubmed #28697241.

ABSTRACT: -- No abstract --

7 Editorial Are We Doing a Good Job? In Praise of Program Evaluation. 2017

Moye, Jennifer. ·a VA Boston Healthcare System and Harvard Medical School , Boston , Massachusetts , USA. ·Clin Gerontol · Pubmed #28452669.

ABSTRACT: -- No abstract --

8 Editorial Shifting Paradigms About Hormonal Risk Factors for Postmenopausal Depression: Age at Menopause as an Indicator of Cumulative Lifetime Exposure to Female Reproductive Hormones. 2016

Joffe, Hadine / Bromberger, Joyce T. ·Department of Psychiatry, Brigham and Women's Hospital, Boston, Massachusetts2Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. · Department of Epidemiology, University of Pittsburgh, Pittsburgh, Pennsylvania4Department of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania. ·JAMA Psychiatry · Pubmed #26746695.

ABSTRACT: -- No abstract --

9 Editorial Late-Life Depression and Antidepressants. 2015

Salzman, Carl. ·Department of Psychiatry, Massachusetts Mental Health Center, Boston, MA. Electronic address: carl_salzman@hms.harvard.edu. ·Am J Geriatr Psychiatry · Pubmed #26424383.

ABSTRACT: -- No abstract --

10 Editorial Implications of a Biosignature Study of the Placebo Response in Major Depressive Disorder. 2015

Fava, Maurizio. ·Massachusetts General Hospital, Boston2Harvard Medical School, Boston, Massachusetts. ·JAMA Psychiatry · Pubmed #26421499.

ABSTRACT: -- No abstract --

11 Editorial Depression in cardiovascular disease: From awareness to action. 2015

Huffman, Jeff C / Celano, Christopher M. ·Department of Psychiatry, Massachusetts General Hospital, Boston, MA; Department of Psychiatry, Harvard Medical School, Boston, MA. ·Trends Cardiovasc Med · Pubmed #25910599.

ABSTRACT: -- No abstract --

12 Editorial Can the effects of noninvasive brain stimulation alleviating neuropsychiatric symptoms result from a common beneficial regulation of the hypothalamic-pituitary-adrenal axis? 2015

Brunelin, Jerome / Fecteau, Shirley. ·Centre interdisciplinaire de recherche en réadaptation et en intégration sociale (CIRRIS) de l'Université Laval, Canada; Centre de recherche de l'Institut universitaire en santé mentale de Québec, Canada; Faculté de médecine, Université Laval, 1050, Avenue de la Médecine, Quebec, Quebec, Canada G1V0A6; Centre Hospitalier le Vinatier, Université de Lyon, EA 4615, F-69003, France; Université Claude Bernard Lyon I, Bron, France. Electronic address: jerome.brunelin@ch-le-vinatier.fr. · Centre interdisciplinaire de recherche en réadaptation et en intégration sociale (CIRRIS) de l'Université Laval, Canada; Centre de recherche de l'Institut universitaire en santé mentale de Québec, Canada; Faculté de médecine, Université Laval, 1050, Avenue de la Médecine, Quebec, Quebec, Canada G1V0A6; Berenson-Allen Center for Noninvasive Brain Stimulation, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. ·Brain Stimul · Pubmed #25556003.

ABSTRACT: -- No abstract --

13 Editorial Racial and ethnic diversity in studies of late-life mental health. 2014

Okereke, Olivia I. ·Channing Division of Network Medicine, Department of Medicine, and Department of Psychiatry, Brigham and Women's Hospital, and Harvard Medical School, and Department of Epidemiology, Harvard School of Public Health, Boston, MA. Electronic address: ookereke@partners.org. ·Am J Geriatr Psychiatry · Pubmed #24927878.

ABSTRACT: -- No abstract --

14 Editorial Stigma and mental illness. 2014

Seidman, Larry J. ·Beth Israel Deaconess Medical Center, Massachusetts Mental Health Center and Harvard Medical School, Boston, MA, USA. ·Asian J Psychiatr · Pubmed #24813027.

ABSTRACT: -- No abstract --

15 Editorial SMART designs in observational studies of opioid therapy duration. 2014

Jackson, John W / Gagne, Joshua J. ·Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 1620 Tremont Street, Suite 3030, Boston, MA, 02120, USA. ·J Gen Intern Med · Pubmed #24449033.

ABSTRACT: -- No abstract --

16 Editorial When depression doesn't lead with depression. 2013

Miller, Michael Craig. ·Harvard Medical School, Boston, Massachusetts. ·JAMA Psychiatry · Pubmed #24173599.

ABSTRACT: -- No abstract --

17 Editorial Biological embedding of early life adversity. 2013

Nelson, Charles A. ·Boston Children's Hospital/Harvard Medical School, Harvard Center on the Developing Child, Boston, Massachusetts. ·JAMA Pediatr · Pubmed #24165859.

ABSTRACT: -- No abstract --

18 Editorial Commentary: "electroconvulsive stimulation (ECS) increases the expression of neuropeptide Y (NPY) in rat brains in a model of neuropathic pain: a quantitative real-time polymerase chain reaction (RT-PCR) study," by Okabe and colleagues. 2009

Wasan, Ajay D. ·Section of Clinical Pain Research, Brigham and Women's Hospital and Harvard Medical School, USA. ·Pain Med · Pubmed #20021602.

ABSTRACT: -- No abstract --

19 Review Does obtaining CYP2D6 and CYP2C19 pharmacogenetic testing predict antidepressant response or adverse drug reactions? 2019

Solomon, Haley V / Cates, Kevin W / Li, Kevin J. ·Harvard South Shore Psychiatry Residency Training Program, Brockton, MA, USA; Department of Psychiatry, Veterans Affairs Boston Healthcare System, Boston, MA, USA; Department of Psychiatry, Harvard Medical School, Boston, MA, USA. ·Psychiatry Res · Pubmed #30554109.

ABSTRACT: Treatment non-response and adverse reactions are common in patients receiving antidepressants. Personalizing psychiatric treatment based on pharmacogenetic testing has been proposed to help clinicians guide antidepressant selection and dosing. This systematic literature review assesses the two most robustly studied drug-metabolizing enzymes, CYP2D6 and CYP2C19, and examines whether obtaining CYP2D6 and CYP2C19 testing can be used to predict antidepressant response or adverse drug reactions in order to improve clinical outcomes. In general, literature reviews published prior to 2013 indicated that results have been inconsistent linking CYP2D6 and CYP2C19 to antidepressant treatment outcomes, suggesting that more evidence is required to support the clinical implementation of genotyping to predict outcomes. We thus performed an extensive and systematic literature review, focusing on studies published from 2013 through 2018. Sixteen studies were found to be relevant. The results yielded inconsistent findings, suggesting that CYP2D6 and CYP2C19 testing may predict response in certain individuals, but it remains unclear if this will translate to improved clinical outcomes. Further research is required to determine when pharmacogenetic testing should be utilized and in which populations it is indicated. Randomized, controlled, prospective trials with adequate sample sizes would best clarify whether genotype-guided antidepressant selection will ultimately improve clinical outcomes.

20 Review Tachyphylaxis in major depressive disorder: A review of the current state of research. 2019

Kinrys, Gustavo / Gold, Alexandra K / Pisano, Vincent D / Freeman, Marlene P / Papakostas, George I / Mischoulon, David / Nierenberg, Andrew A / Fava, Maurizio. ·Clinical Trials Network and Institute, Massachusetts General Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA. Electronic address: gkinrys@mgh.harvard.edu. · Department of Psychological & Brain Sciences, Boston University, Boston, MA, USA. · Clinical Trials Network and Institute, Massachusetts General Hospital, Boston, MA, USA. · Clinical Trials Network and Institute, Massachusetts General Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA. · Clinical Trials Network and Institute, Massachusetts General Hospital, Boston, MA, USA; Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA. ·J Affect Disord · Pubmed #30439676.

ABSTRACT: BACKGROUND: Patients with major depressive disorder (MDD) often experience a re-emergence or worsening of symptoms despite ongoing treatment with previously effective antidepressant pharmacotherapy. This lost or reduced antidepressant response during maintenance, referred to as tachyphylaxis, negatively impacts treatment outcomes and quality of life for patients with MDD. This review assesses the prevalence of antidepressant tachyphylaxis as well as the evidence for interventions to manage it. METHODS: We searched PubMed/Medline for the relevant clinical trials and meta-analyses on antidepressant tachyphylaxis up to January 2017. Search terms included "depression" paired with "treatment" (n = 186,674), "tachyphylaxis" paired with "depression" (n = 112), "tachyphylaxis" paired with "major depressive disorder" (n = 21), and "antidepressant" paired with "tachyphylaxis" (n = 68). Studies were included if they reported on a clinical trial or meta-analysis exploring tachyphylaxis in MDD and were excluded if the sample population did not have a primary DSM diagnosis of MDD. RESULTS: Rates of tachyphylaxis varied from 9% to 57% depending on the patient population and duration of follow-up. Limited evidence suggests potentially beneficial strategies for managing tachyphylaxis, including change in antidepressant dosing, switch of class of antidepressant medication, augmentation or combination pharmacotherapy, and psychotherapy. LIMITATIONS: Studies of antidepressant tachyphylaxis are largely heterogeneous in nature and employ strict inclusion/exclusion criteria; thus, these findings may not be generalizable to all depressed populations. CONCLUSION: Few established treatment strategies exist to manage antidepressant tachyphylaxis. Further interventional research is needed to provide symptomatic relief for patients with tachyphylaxis in MDD.

21 Review Transcranial and systemic photobiomodulation for major depressive disorder: A systematic review of efficacy, tolerability and biological mechanisms. 2019

Caldieraro, Marco A / Cassano, Paolo. ·Serviço de Psiquiatria, Hospital de Clínicas de Porto Alegre. Rua Ramiro Barcelos 2350, Porto Alegre, RS 90035-903, Brazil. Electronic address: mcaldieraro@hcpa.edu.br. · Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital. 1 Bowdoin Square, Boston, MA 02114, USA; Center for Anxiety and Traumatic Stress Disorders, Department of Psychiatry, Massachusetts General Hospital, Boston. 1 Bowdoin Square, MA 02114, USA. ·J Affect Disord · Pubmed #30248638.

ABSTRACT: BACKGROUND: Photobiomodulation (PBM) with red and near-infrared light (NIR) -also known as Low-Level Light Therapy-is a low risk, inexpensive treatment-based on non-retinal exposure-under study for several neuropsychiatric conditions. The aim of this paper is to discuss the proposed mechanism of action and to perform a systematic review of pre-clinical and clinical studies on PBM for major depressive disorder (MDD). METHODS: A search on MEDLINE and EMBASE databases was performed in July 2017. No time or language restrictions were used. Studies with a primary focus on MDD and presenting original data were included (n = 17). References on the mechanisms of action of PBM also included review articles and studies not focused on MDD. RESULTS: Red and NIR light penetrate the skull and modulate brain cortex; an indirect effect of red and NIR light, when delivered non-transcranially, is also postulated. The main proposed mechanism for PBM is the enhancement of mitochondrial metabolism after absorption of NIR energy by the cytochrome C oxidase; however, actions on other pathways relevant to MDD are also reported. Studies on animal models indicate a benefit from PBM that is comparable to antidepressant medications. Clinical studies also indicate a significant antidepressant effect and good tolerability. LIMITATIONS: Clinical studies are heterogeneous for population and treatment parameters, and most lack an appropriate control. CONCLUSIONS: Preliminary evidence supports the potential of non-retinal PBM as a novel treatment for MDD. Future studies should clarify the ideal stimulation parameters as well as the overall efficacy, effectiveness and safety profile of this treatment.

22 Review Sex differences in major depression and comorbidity of cardiometabolic disorders: impact of prenatal stress and immune exposures. 2019

Goldstein, Jill M / Hale, Taben / Foster, Simmie L / Tobet, Stuart A / Handa, Robert J. ·Departments of Psychiatry and Obstetrics and Gynecology, Massachusetts General Hospital (MGH), Boston, MA, 02120, USA. jill_goldstein@hms.harvard.edu. · Departments of Psychiatry and Medicine, Harvard Medical School, Boston, MA, USA. jill_goldstein@hms.harvard.edu. · Department of Basic Medical Science, University of Arizona College of Medicine - Phoenix, Phoenix, AZ, 85004, USA. · Department of Psychiatry, Harvard Medical School, at Massachusetts General Hospital, Boston, MA, USA. · Department of Biomedical Sciences, Colorado State University, Fort Collins, CO, 80523, USA. · School of Biomedical Engineering, Colorado State University, Fort Collins, CO, 80523, USA. ·Neuropsychopharmacology · Pubmed #30030541.

ABSTRACT: Major depressive disorder topped ischemic heart disease as the number one cause of disability worldwide in 2012, and women have twice the risk of men. Further, the comorbidity of depression and cardiometabolic disorders will be one of the primary causes of disability worldwide by 2020, with women at twice the risk. Thus, understanding the sex-dependent comorbidities has public health consequences worldwide. We propose here that sex differences in MDD-cardiometabolic comorbidity originate, in part, from pathogenic processes initiated in fetal development that involve sex differences in shared pathophysiology between the brain, the vascular system, the CNS control of the heart and associated hormonal, immune, and metabolic physiology. Pathways implicate neurotrophic and angiogenic growth factors, gonadal hormone receptors, and neurotransmitters such as gamma amino butyric acid (GABA) on neuronal and vascular development of HPA axis regions, such as the paraventricular nucleus (PVN), in addition to blood pressure, in part through the renin-angiotensin system, and insulin and glucose metabolism. We show that the same prenatal exposures have consequences for sex differences across multiple organ systems that, in part, share common pathophysiology. Thus, we believe that applying a sex differences lens to understanding shared biologic substrates underlying these comorbidities will provide novel insights into the development of sex-dependent therapeutics. Further, taking a lifespan perspective beginning in fetal development provides the opportunity to target abnormalities early in the natural history of these disorders in a sex-dependent way.

23 Review Inflammatory Signaling in Post-Stroke Fatigue and Depression. 2018

Wen, Hongmei / Weymann, Kristianna B / Wood, Lisa / Wang, Qing Mei. ·Department of Rehabilitation Medicine, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China. · Oregon Health and Science University, Portland, Oregon, USA. · School of Nursing, MGH Institute of Health Professions, Boston, Massachusetts, USA. · Stroke Biological Recovery Laboratory, Spaulding Rehabilitation Hospital, Harvard Medical School, Boston, Massachusetts, USA, wang.qingmei@mgh.harvard.edu. ·Eur Neurol · Pubmed #30448848.

ABSTRACT: BACKGROUND: In the United States, stroke continues to be the cause for long-term disability. Of the patients with a first stroke, up to 75% will experience post-stroke fatigue (PSF) in the first year following stroke. PSF is one of the most disabling symptoms in stroke survivors; it decreases quality of life, increases mortality, and is a barrier to stroke rehabilitation. Given the incidence of stroke and the prevalence and detrimental impact of PSF on quality of life, independent living, and overall survival, efficient management of PSF must be a priority in stroke rehabilitation. The cause of PSF remains unknown. The burden of fatigue in stroke survivors is influenced by other stroke-related symptoms, most notably post-stroke depression (PSD). It is well known that stroke induces a systemic inflammatory response that is the trigger for sickness behavior, of which fatigue and depression are predominant symptoms. SUMMARY: To date, only a handful of studies have sought to explore the relationship between stroke-induced inflammation and PSF and PSD. In this review, we describe this evidence, highlight the strengths and weaknesses of these existing studies, and suggest further experiments that may further support the association between stroke-related inflammatory processes and stroke-related symptoms. Key Messages: The current concept and further research are important for a more specific therapeutic intervention for PSF and PSD.

24 Review Cognitive dysfunction and migraine. 2018

Vuralli, Doga / Ayata, Cenk / Bolay, Hayrunnisa. ·Department of Neurology and Algology, Gazi University Faculty of Medicine, Besevler, 06510, Ankara, Turkey. · Neuropsychiatry Center, Gazi University, Besevler, 06510, Ankara, Turkey. · Neurovascular Research Lab, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA. · Stroke Service, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA. · Department of Neurology and Algology, Gazi University Faculty of Medicine, Besevler, 06510, Ankara, Turkey. hbolay@gazi.edu.tr. · Neuropsychiatry Center, Gazi University, Besevler, 06510, Ankara, Turkey. hbolay@gazi.edu.tr. ·J Headache Pain · Pubmed #30442090.

ABSTRACT: Cognitive dysfunction has recently gained attention as a significant problem among migraine sufferers. All of the clinical studies show poor cognitive performance during migraine attacks, though, the interictal data are conflicting. Migraineurs show impaired cognitive function interictally in most of the clinic-based studies. Population-based studies did not reveal a difference in cognitive functions between migraineurs and controls. The specific cognitive domains involved are information processing speed, basic attention, executive functions, verbal and non-verbal memory and verbal skills. Neurophysiological, imaging and pharmacological studies support clinical symptoms of cognitive impairment in migraine. Longitudinal studies do not suggest progressive cognitive decline over time in migraine patients. Preventive medications and comorbid disorders such as depression and anxiety can impact cognitive function, but cannot fully explain the cognitive impairment in migraine. In contrast to migraine, tension type or cluster headache are not associated with cognitive impairment, at least during headache-free periods.

25 Review Deep Brain Stimulation: Clinical Applications. 2018

Dougherty, Darin D. ·Division of Neurotherapeutics, Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, CNY2612, 149 13th Street, Boston, MA 02129, USA. Electronic address: ddougherty@partners.org. ·Psychiatr Clin North Am · Pubmed #30098652.

ABSTRACT: Deep brain stimulation has been used for decades in neurology to treat movement disorders. More recent work has focused on developing applications for deep brain stimulation in psychiatric illness. Initial studies have demonstrated positive results for treatment-refractory obsessive-compulsive disorder. Initial open-label studies of deep brain stimulation at targets for treatment-resistant depression have been encouraging. However, the only 2 published controlled trials that were conducted for potential FDA approval for treatment-resistant depression were both negative. Future directions include potential use of alternate clinical trial designs, using tractography for more refined deep brain stimulation electrode targeting, and closed-loop deep brain stimulation approaches.

Next